Senti Biosciences, Inc. announced strategic plan to focus research and development efforts on lead oncology candidate SENTI-202 for the treatment CD33 and/or FLT3 expressing hematologic malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), to continue to advance SENTI-401 through preclinical studies to target colorectal cancer and other CEA-positive solid tumors, and to pursue strategic geographic partnerships for clinical development of SENTI-301A for liver cancer, of which there is high prevalence in Asian territories.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3689 USD | -0.30% | -0.30% | -44.11% |
1st Jan change | Capi. | |
---|---|---|
-44.11% | 16.88M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- SNTI Stock
- News Senti Biosciences, Inc.
- Senti Biosciences, Inc. Announces Strategic Plan to Focus Research and Development Efforts on Lead Oncology Candidate SENTI-202